{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:41:20Z","timestamp":1786718480902,"version":"build-2736575974"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Perspect Clin Res"],"published-print":{"date-parts":[[2018]]},"DOI":"10.4103\/picr.picr_156_16","type":"journal-article","created":{"date-parts":[[2018,1,24]],"date-time":"2018-01-24T08:02:16Z","timestamp":1516780936000},"page":"23","source":"Crossref","is-referenced-by-count":12,"title":["Pattern and impact of drugs targeted toward toxicity amelioration in patients receiving cancer chemotherapy"],"prefix":"10.4103","volume":"9","author":[{"given":"PrashantKumar","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/2229-3485.223938-1","unstructured":"WHO. Non Communicable Diseases; 2012. Available from: http:\/\/www.who.int\/mediacentre\/factsheets\/fs355\/. [Last accessed on 2017 Apr 25]."},{"key":"key-10.4103\/2229-3485.223938-2","first-page":"S13","volume-title":"Social and economic implications of noncommunicable diseases in India","author":"Thakur","year":"2011","journal-title":"Indian J Community Med","ISSN":"https:\/\/id.crossref.org\/issn\/0970-0218","issn-type":"print"},{"key":"key-10.4103\/2229-3485.223938-3","unstructured":"Non-Communicable Diseases Such as Cancer 'are the Leading Global Killer'. London: Cancer Research UK; 2012. Available from: http:\/\/www.cancerresearchuk.org\/cancer-info\/news\/archive\/cancernews\/. [Last cited on 2012 Dec 25]."},{"key":"key-10.4103\/2229-3485.223938-4","unstructured":"Moss D. Coley's Toxins, Burzynski, and Cancer Politics. (Laura Lee Radio Show, Homepage). New York: 1994. Available from: http:\/\/www.whale.to\/c\/moss.html. [Last accessed on 2017 Apr 25]."},{"key":"key-10.4103\/2229-3485.223938-5","unstructured":"William AD. The Design and Development of Anticancer Drugs. ed. 1, Vol. 2. New Zealand: Chemical Processes. Available from: https:\/\/nzic.org.nz\/ChemProcesses\/biotech\/12J.pdf. [Last accessed on 2017 Apr 25]."},{"key":"key-10.4103\/2229-3485.223938-6","first-page":"1375","volume-title":"Despite criticism of the FDA review process, new cancer drugs reach patients sooner in the United States than in Europe","author":"Roberts","year":"2011","journal-title":"Health Aff (Millwood)"},{"key":"key-10.4103\/2229-3485.223938-7","first-page":"33","volume-title":"Biological response modifiers in cancer","author":"Reang","year":"2006","journal-title":"MedGenMed"},{"key":"key-10.4103\/2229-3485.223938-8","first-page":"885","volume-title":"A decade of the fast track programme","author":"Reichert","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"key-10.4103\/2229-3485.223938-9","first-page":"1571","volume-title":"Quality of life instruments in oncology","author":"Velikova","year":"1999","journal-title":"Eur J Cancer"},{"key":"key-10.4103\/2229-3485.223938-10","first-page":"635","volume-title":"Adverse effects of anticancer drugs: Apropos of a pharmacovigilance study at a specialized oncology institution","author":"Couffignal","year":"2000","journal-title":"Therapie"},{"key":"key-10.4103\/2229-3485.223938-11","first-page":"1","volume-title":"Monitoring of suspected adverse drug reactions in oncology unit of an urban multispeciality teaching hospital","author":"De","year":"2010","journal-title":"Int J Res Pharm Biomed Sci"},{"key":"key-10.4103\/2229-3485.223938-12","unstructured":"The CIOMS International Ethical Guidelines for Biomedical Research. Available from: http:\/\/www.ciom.ch\/publications\/guidelines\/guideline-nov-2002-blurb.htm. [Last accessed on 2017 Apr 25]."},{"key":"key-10.4103\/2229-3485.223938-13","first-page":"538","volume-title":"Focusing on the preventability of adverse drug reactions","author":"Schumock","year":"1992","journal-title":"Hosp Pharm"},{"key":"key-10.4103\/2229-3485.223938-14","first-page":"46","volume-title":"Hospitalisations caused by adverse drug reactions (ADR): A meta-analysis of observational studies","author":"Beijer","year":"2002","journal-title":"Pharm World Sci"},{"key":"key-10.4103\/2229-3485.223938-15","first-page":"40","volume-title":"Adverse drug reaction profile of cisplatin-based chemotherapy regimen in a tertiary care hospital in India: An evaluative study","author":"Surendiran","year":"2010","journal-title":"Indian J Pharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0253-7613","issn-type":"print"},{"key":"key-10.4103\/2229-3485.223938-16","first-page":"626","volume-title":"The ten most common adverse drug reactions (ADRs) in oncology patients: Do they matter to you?","author":"Lau","year":"2004","journal-title":"Support Care Cancer"},{"key":"key-10.4103\/2229-3485.223938-17","first-page":"4112","volume-title":"The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin \u2013 The Aprepitant Protocol 052 Study Group","author":"Hesketh","year":"2003","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/2229-3485.223938-18","first-page":"276","volume-title":"The role of mannitol as a nephroprotectant in patients receiving cisplatin therapy","author":"Morgan","year":"2012","journal-title":"Ann Pharmacother"},{"key":"key-10.4103\/2229-3485.223938-19","first-page":"531","volume-title":"Partial reversibility of cisplatin nephrotoxicity in children","author":"Brock","year":"1991","journal-title":"J Pediatr"},{"key":"key-10.4103\/2229-3485.223938-20","unstructured":"Gaby AR. Magnesium Prevents Chemotherapy Side Effects. Available from http:\/\/www.magtabsr.com\/wp-content\/uploads\/2016\/04\/Magnesium-prevents-chemotherapy-side-effects.pdf. [Last accessed on 2017 Apr 25]."},{"key":"key-10.4103\/2229-3485.223938-21","first-page":"159","volume-title":"Hemorrhagic cystitis: A challenge to the urologist","author":"Manikandan","year":"2010","journal-title":"Indian J Urol","ISSN":"https:\/\/id.crossref.org\/issn\/0970-1591","issn-type":"print"},{"key":"key-10.4103\/2229-3485.223938-22","unstructured":"Carless PA. Proposal for the Inclusion of Mesna (Sodium 2-Mercaptoethane Sulfonate) for the Prevention of Ifosfamide and Cyclophosphamide (Oxazaphosphorine Cytotoxics) Induced Haemorrhagic Cystitis. Geneva: WHO; 2009. Available from: http:\/\/www.who.int\/selection-medicines\/17\/WEB-TRS-DEC-2009.pdf. [Last accessed on 2017 Apr 25]."},{"key":"key-10.4103\/2229-3485.223938-23","first-page":"601","volume-title":"Management and preparedness for infusion and hypersensitivity reactions","author":"Lenz","year":"2007","journal-title":"Oncologist"},{"key":"key-10.4103\/2229-3485.223938-24","unstructured":"Chabner BA. General principles of cancer chemotherapy. In: Brunton LL, Chabner BA, Knollman BC, editors. Goodman & Gilman's the Pharmacological Basis of Therapeutics. 12th ed. New York: McGraw Hill; 2011. p. 1667-77."}],"container-title":["Perspectives in Clinical Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:35:36Z","timestamp":1786714536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/picr.PICR_156_16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"alternative-id":["223938"],"URL":"https:\/\/doi.org\/10.4103\/picr.picr_156_16","relation":{},"ISSN":["2229-3485"],"issn-type":[{"value":"2229-3485","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}